Molecular data
| Molecular formula | C22H21N5O3 |
|---|---|
| Molecular weight | 419.4 Da |
| CAS / identifier | 303760-60-3 |
| Physical form | Encapsulated powder |
| Available sizes | 1000mcg, 500mcg |
How it works
Estrogen-Related Receptor Activation
SLU-PP-332 binds and activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), with greatest potency at ERRα. These orphan nuclear receptors are master transcriptional regulators of cellular energy metabolism.
- Activates ERRα / ERRβ / ERRγ (EC50 98 / 230 / 430 nM)
- Stabilizes the active ERR conformation
- Small molecule — not a peptide
PGC-1α / ERR Transcriptional Axis
ERRα sits downstream of PGC-1α, the master coactivator of mitochondrial biogenesis. Activating the ERR axis upregulates gene programs for mitochondrial biogenesis, fatty-acid β-oxidation, and oxidative phosphorylation.
- Drives mitochondrial biogenesis gene networks
- Enhances fatty-acid β-oxidation and OXPHOS
- Increases oxidative (type IIa) muscle fibers in vivo
Endurance Adaptation Without Training
By switching on the same metabolic gene program that endurance exercise activates, SLU-PP-332 is studied as an "exercise mimetic" — reproducing several adaptations of aerobic training in sedentary animal models.
- Recapitulates the molecular signature of endurance exercise
- Increased energy expenditure and fatty-acid oxidation
- Reduced fat mass without reduced food intake (mice)
What the research shows
Exercise Mimetics & Mitochondrial Biology
Used to probe how pharmacological ERR activation reproduces endurance-exercise adaptations — mitochondrial biogenesis, oxidative fiber formation, and increased fatty-acid oxidation.
Billon et al. 2022
Obesity & Metabolic Syndrome
In diet-induced obese mice, SLU-PP-332 increased energy expenditure and fat oxidation and reduced fat mass without reducing food intake — a model for obesity and metabolic-syndrome research.
Billon et al. 2024
Heart Failure Models
Pan-ERR agonists improved ejection fraction, reduced fibrosis, and increased survival in pressure-overload heart-failure models by boosting cardiac fatty-acid metabolism and mitochondrial function.
Xu et al., Circulation 2024
Endurance & Oxidative Fiber Type
Treated mice ran substantially farther without training and showed a shift toward oxidative (type IIa) muscle fibers, supporting research into skeletal-muscle metabolism and fatigue resistance.
Billon et al. 2022
Specification
| Type | Synthetic small-molecule pan-ERR agonist |
|---|---|
| Receptor Targets | ERRα / ERRβ / ERRγ (estrogen-related receptors) |
| Potency (EC50) | ERRα 98 nM · ERRβ 230 nM · ERRγ 430 nM |
| CAS Number | 303760-60-3 |
| Molecular Formula | C₂₂H₂₁N₅O₃ |
| Molecular Weight | ~419.4 g/mol |
| Developed By | Burris Laboratory, Saint Louis University (2023) |
| Form | Encapsulated powder |
| Content | 1000 mcg or 500 mcg per capsule |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spectrometry |
| Storage | Store cool and dry, protected from light |
| COA | Included with every order |
Frequently asked questions
What is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors (ERRα, ERRβ, ERRγ). It was developed and characterized by the Burris laboratory at Saint Louis University (Billon et al., 2023) as a pharmacological tool for studying ERR biology and mitochondrial energy metabolism. Despite often being grouped with research peptides, it is a small molecule, not a peptide.
How does SLU-PP-332 work?
It binds and activates the ERR family, with highest potency at ERRα. ERRα works downstream of the coactivator PGC-1α to control transcription of genes for mitochondrial biogenesis, fatty-acid β-oxidation, and oxidative phosphorylation. Activating this axis reproduces much of the gene-expression program normally triggered by endurance exercise.
Why is it called an "exercise mimetic"?
In sedentary mice, SLU-PP-332 switched on the same metabolic gene networks that endurance training activates and produced several similar adaptations — increased running endurance, more oxidative muscle fibers, higher energy expenditure, and reduced fat mass. Because it mimics exercise-induced changes pharmacologically, researchers describe it as an "exercise mimetic." This is a research concept, not a substitute for exercise.
What has preclinical research shown?
Rodent studies report roughly 20–30% greater running endurance without training, a shift toward oxidative type IIa muscle fibers, increased energy expenditure and fatty-acid oxidation, and reduced fat mass without reduced food intake. Related pan-ERR agonists also improved cardiac function and survival in heart-failure models. All findings are preclinical.
Is SLU-PP-332 FDA-approved?
No. SLU-PP-332 is an early-stage research chemical. It has not undergone human clinical trials and is not approved for human or veterinary use. It is sold strictly for in vitro and preclinical laboratory research.
How should SLU-PP-332 be stored?
Store the material cool, dry, and protected from light and moisture for long-term stability. Handle and reconstitute according to standard laboratory protocols for the intended assay. A certificate of analysis is included with every order.
Literature
- JOURNAL A Synthetic ERR Agonist Alleviates Metabolic Syndrome
- PREPRINT A Synthetic ERRα Agonist Induces an Acute Aerobic Exercise Response and Enhances Exercise Capacity
- JOURNAL Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
- DATABASE SLU-PP-332 — Compound Record (CAS 303760-60-3)
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.